A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults.

Trial Profile

A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium in the Treatment of Diabetic Foot Infections in Chinese Adults.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Ertapenem (Primary) ; Piperacillin/tazobactam
  • Indications Bacterial infections; Diabetic foot ulcer; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Feb 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 27 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Dec 2013 Planned end date changed from 1 Feb 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top